Company Developments - Zimmer Biomet Holdings Inc (ZBH) received FDA 510(k) clearance for its Persona SoluTion PPS Femur, a total knee implant component designed for patients with sensitivities to bone cement and/or metal [1] - The company expects to commercially launch Persona SoluTion PPS Femur in the United States in Q1 2025 [1] - ZBH recently received FDA Premarket Approval Application Supplement approval for the Oxford Cementless Partial Knee, making it the only FDA-approved cementless partial knee implant in the United States [8] Product Details - Persona SoluTion PPS Femur combines cementless fixation with PPS coating, providing initial scratch fit stability and supporting biological fixation through bony growth [5] - The implant minimizes common metal sensitizers by combining with Persona OsseoTi tibia and Vivacit-E Highly Crosslinked Polyethylene (HXLPE) [6] - The implant is made of Tivanium (Ti-6Al-4V) alloy with over 17 years of clinical use, treated with the Ti-Nidium Surface Hardening Process [6] Market Performance - ZBH shares moved 0.1% lower to $110.62 following the announcement [2] - The company has a market capitalization of $22.09 billion [3] - ZBH shares have lost 4.5% in the past year, compared to the industry's 21% growth [9] Financial Performance - ZBH's earnings surpassed estimates in three of the trailing four quarters, with an average surprise of 1.76% [3] Industry Outlook - The global knee replacement market is expected to reach $16.99 billion by 2031, growing at a CAGR of 5.67% during 2024-2031 [7] - Key growth drivers include rising incidence of osteoarthritis and increasing demand for joint replacement surgeries [7]

Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration (“FDA”) Premarket Approval Application (“PMA”) Supplement approval for the Oxford Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (“IDE”) study and non-clinical testing for cementless partial knee replacement (“PKR”).With this, Oxford Cementless Partial Knee becomes the only FDA-approved cementless partial knee implant in the United States. The latest FDA ...

Core Viewpoint - Zimmer Biomet Holdings, Inc. has received the CE Mark for its Persona® Revision Knee System, enhancing its commitment to personalized medical solutions for revision knee arthroplasty [1][2]. Group 1: Product Launch and Features - The Persona Revision Knee System is designed to provide a personalized fit and optimized function for patients undergoing revision knee surgery, featuring modular components for intraoperative flexibility [3][4]. - The system incorporates Zimmer Biomet's proprietary Trabecular Metal™ Technology, which supports long-term bone in-growth and improves implant fixation [3]. - The Persona Revision Knee is positioned as a leading product in the over $700 million U.S. knee revision market, streamlining the revision surgery process and improving precision [4]. Group 2: Company Mission and Vision - The launch of the Persona Revision Knee System aligns with Zimmer Biomet's mission to alleviate pain and enhance the quality of life for patients globally through innovative solutions [5]. - With over 90 years of experience, Zimmer Biomet aims to deliver high-quality medical technology solutions, leveraging data analytics and artificial intelligence to transform patient experiences [6][7].

Core Viewpoint - Zimmer Biomet's strategic product launches and stabilizing market trends enhance confidence in the stock, despite macroeconomic uncertainties impacting the bottom line [1] Factors Driving ZBH's Share Price - Zimmer Biomet is gaining strong market share in reconstructive knees and hips across key geographies, with revenues growing mid-single digits for 11 consecutive quarters [2] - The international business exceeded sales expectations in Q3 2024, driven by strong demand in reconstructive knees, hips, and S.E.T. categories [2] - The knee business grew 10% internationally in the quarter, despite challenges from ERP system implementation [3] - Upcoming product launches, such as the Oxford Partial cementless Knee in 2025, are expected to capture 60% of the European market [3] - Anticipated launches of Z1 HAMMR and Navigation products are expected to drive market share in hips [3] - The company is focusing on the ROSA Robotic Platform combined with the Persona cementless Knee, aiming to increase robotics and cementless penetration from 20% to 50%-60% [5] Factors Affecting ZBH's Growth - Industry-wide staffing shortages and supply chain issues are negatively impacting growth [8] - Geopolitical complications and high interest rates are affecting raw material and labor costs, particularly in the dental treatment space [8] - Challenges in the hip category due to headwinds in Russia are impacting international business [8] - Reimbursement headwinds in the Restorative Therapies business are creating challenges within the S.E.T. category [8] - Acute supply challenges in Sports and Trauma are also pressuring revenues and operating profit [8] Financial Performance - In Q3, Zimmer Biomet experienced a 3.9% increase in cost of products sold and a 3.1% rise in selling, general, and administrative expenses [9] - Adjusted gross margin contracted by 34 basis points, while adjusted operating margin contracted by 18 basis points [9] - Foreign exchange fluctuations negatively impacted net sales by 0.1% in Q3 2024, with an expected adverse impact of 75 basis points for the full year [10]

Zimmer Biomet Holdings, Inc. (ZBH) posted third-quarter 2024 adjusted earnings per share (EPS) of $1.74, missing the Zacks Consensus Estimate by 0.6%. However, the adjusted figure increased 5.5% year over year. The quarter's adjustments included certain amortization, restructuring and other cost reduction initiatives and European Union Medical Device Regulation-related charges, among others. On a reported basis, the company registered earnings of $1.23 per share, compared to 77 cents in the year-ago period. ...

Financial Data and Key Metrics Changes - In Q3 2024, net sales were $1.824 billion, an increase of 4% on a reported basis and 4.1% excluding foreign currency impact [25] - Adjusted diluted earnings per share (EPS) was $1.74, compared to $1.65 in the prior year, indicating earnings grew faster than revenue [30] - Free cash flow for the quarter was $310 million, bringing year-to-date free cash flow to $652 million [32] Business Line Data and Key Metrics Changes - The combined knee and hip businesses, referred to as the reconstructed platform, grew in the mid-single-digit range globally, while the head segment delivered upper single-digit growth [9] - The S.E.T. segment grew 7.3%, led by CMFT, sports, and upper extremities, marking the fourth consecutive quarter of at least mid-single-digit growth [29] - The "other" category declined by 9.5%, primarily due to difficult comparisons from the prior year and ERP-related challenges [29] Market Data and Key Metrics Changes - The U.S. business grew by 2%, while international sales grew by 7.1%, with strength across knee and S.E.T. segments [26] - Global knees grew by 5.5%, with U.S. growth at 2.9% and international growth at 9.2% [26] - Global hips grew by 3.7%, with U.S. growth at 4.9% and international growth at 2.4% [27] Company Strategy and Development Direction - The company is focused on three strategic priorities: people and culture, operational excellence, and innovation and diversification [16] - The company plans to maintain mid-single-digit revenue growth and adjusted EPS growth of at least 1.5 times revenue through 2027 [19] - The innovation pipeline includes over 50 meaningful product launches, with a strong emphasis on the hips platform and robotics [11][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resolution of ERP challenges and anticipates returning to normal shipping levels by the end of 2024 [8] - The company expects continued market growth driven by an aging population and technological advancements [10] - Management remains optimistic about 2025, citing new product introductions and the resolution of ERP issues as key factors [42] Other Important Information - The company repurchased approximately $600 million in shares during Q3, with over $850 million repurchased through the end of October [33] - The company updated its 2024 guidance, expecting constant currency revenue growth of 4.25% to 4.75% [34] Q&A Session Summary Question: Why is the guidance cut more than the ERP issue for 2024? - Management indicated a conservative approach due to various factors, including pricing dynamics and recent disruptions [39] Question: What are the updated thoughts on M&A? - Management stated that while they do not need to pursue M&A to maintain growth, they are open to opportunities that make strategic and financial sense [45][46] Question: Can you provide insights into the reconstructive businesses, particularly knees? - Management confirmed recovery from previous supply chain issues and expressed optimism for knee performance moving forward [50] Question: What are the expectations for pricing in the U.S.? - Management noted positive pricing trends and structural improvements leading to better performance [86] Question: What impact is volume-based purchasing in China having? - Management reported that China represents 2% to 3% of global sales and has not significantly impacted revenue expectations [91]

For the quarter ended September 2024, Zimmer Biomet (ZBH) reported revenue of $1.82 billion, up 4% over the same period last year. EPS came in at $1.74, compared to $1.65 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.8 billion, representing a surprise of +1.12%. The company delivered an EPS surprise of -0.57%, with the consensus EPS estimate being $1.75.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.57%. A quarter ago, it was expected that this orthopedic device maker would post earnings of $1.98 per share when it actually produced earnings of $2.01, delivering a surprise of 1.52%. Over the last four quarters ...

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 heather.zoumaslubeski@zimmerbiomet.com david.demartino@zimmerbiomet.com Zach Weiner (908) 591-6955 zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Third Quarter 2024 Financial Results • Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency 1 basis • Third quarter diluted earnings per share were $1.23; adjusted 1 dilute ...

In its upcoming report, Zimmer Biomet (ZBH) is predicted by Wall Street analysts to post quarterly earnings of $1.75 per share, reflecting an increase of 6.1% compared to the same period last year. Revenues are forecasted to be $1.8 billion, representing a year-over-year increase of 2.9%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during ...